Epigenetic alterations and anti-epigenetic therapy in myelofibrosis

References

• Stindl R. Defining the steps that lead to cancer: replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells. Med Hypotheses 2008; 71: 126–140
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman J W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gilliland D G. Oncogenes in myeloproliferative disorders. Cell Cycle 2007; 6: 550–566
   PubMed Web of Science ®Google Scholar
• Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
   PubMed Web of Science ®Google Scholar
• Pardanani A, Brockman S R, Paternoster S F, Flynn H C, Ketterling R P, Lasho T L, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038–3045
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008; 49: 388–397
   PubMed Web of Science ®Google Scholar
• Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008; 83: 491–497
   PubMed Web of Science ®Google Scholar
• Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23–30
   PubMed Web of Science ®Google Scholar
• Silverman L R, Demakos E P, Peterson B L, Kornblith A B, Holland J C, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa J P, Rosenfeld C S, Bennett J M, Albitar M, Dipersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803
   PubMed Web of Science ®Google Scholar
• Ihalainen J, Juvonen E, Savolainen E R, Ruutu T, Palotie A. Calcitonin gene methylation in chronic myeloproliferative disorders. Leukemia 1994; 8: 230–235
   PubMed Web of Science ®Google Scholar
• Wang J C, Chen W, Nallusamy S, Chen C, Novetsky A D. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 2002; 116: 582–586
   PubMed Web of Science ®Google Scholar
• Kumagai T, Tefferi A, Jones L, Koeffler H P. Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res 2005; 29: 511–515
   PubMed Web of Science ®Google Scholar
• Jones L C, Tefferi A, Idos G E, Kumagai T, Hofmann W K, Koeffler H P. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 2004; 23: 7846–7853
   PubMed Web of Science ®Google Scholar
• Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 2008; 26: 1920–1930
   PubMed Web of Science ®Google Scholar
• Fourouclas N, J Li, Gilby D C, Campbell P J, Beer P A, Boyd E M, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008; 93: 1635–1644
   PubMed Web of Science ®Google Scholar
• Wang J C, Chen C, Dumlao T, Naik S, Chang T, Xiao Y -Y, et al. Enhanced histone deacytlase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008; 49: 2321–2327
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 2007; 67: 6417–6424
   PubMed Web of Science ®Google Scholar
• Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740–747
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008; 22: 965–970
   PubMed Web of Science ®Google Scholar
• Mesa R A, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia, in press
   Web of Science ®Google Scholar